10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2026)

10x Genomics has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $9.7 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 23.66% year-over-year to $9.7 million; the TTM figure through Jun 2026 stood at $40.0 million (up 19.17% YoY), while the FY2025 annual figure was $36.2 million, up 0.89% from the prior year.
• Depreciation & Amortization (CF) came in at $9.7 million for Q2 2026 at 10x Genomics, down from $10.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.3 million in Q3 2025 to a low of $6.2 million in Q3 2022.
• Average Depreciation & Amortization (CF) over 5 years is $8.5 million, with a median of $9.0 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) soared 52.94% in 2023 and slipped 12.89% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $6.5 million in 2022, then jumped by 49.01% to $9.7 million in 2023, then decreased by 9.95% to $8.8 million in 2024, then grew by 15.03% to $10.1 million in 2025, then retreated by 3.98% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $9.7 million in Q2 2026, $10.0 million in Q1 2026, and $10.1 million in Q4 2025.